Please try another search
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Rui-Wen Wu | - | 2018 | Representative Director |
Ming-Feng Hou | - | 2021 | Director |
Yi-Hui Lin | - | 2018 | Representative Director |
Chih-Li Wang | - | 2019 | Independent Director |
Chien-Huang Lin | - | 2021 | Independent Director |
Ming-Daw Chang | - | - | Independent Director |
Wen-Hung Hsu | - | - | Representative Director |
Ming-Shiang Wu | - | - | Representative Director |
Zhangyao Xu | - | - | Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review